Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN Symposium 2018 /
Beyond standard of care: the next steps of Precision Oncology

25th - 26th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.07.18
Views: 1254

Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dr Tabernero speaks with ecancer at the 2018 WIN symposium about the process of drug approval, and how this is being streamlined to prioritise breakthrough therapy.

He discusses them from the perspective as ESMO, how this process varies across the world, and how communication can be improved globally.

Dr Tabernero finishes by discussing how progress will be reported at this years' ESMO in Munich in October.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation